Principal Investigator
Valeria Santini, Prof.
University of Careggi, Italy
Total Trials
1
As PI
1
Completed
0
h-index
N/A
Publications
0
Years Active
0
Research Impact
h-index
N/A
Research impact score
Publications
0
Total publications
Trial Results
0
Published trial results
Citations
0
Total citations
Drug Portfolio
DRUG(1)
1 unique interventions1 categories
Analytics
Trial Phases
Phase 21
Trial Status
Other1
Role Distribution
Principal Investigator1
PI Rate100%
Activity Timeline
Clinical Trials (1)
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
Low Risk Myelodysplastic Syndromes
PrincipalinvestigatorStart date: 2024-09-10
Research Network
Collaboration Network
5 collaborators·10 connections
Network Legend
KOL
Current InvestigatorCO
High-influence CollaboratorCO
CollaboratorClick: view details
Double-click: go to profile
Drag: move node
Research Areas & Affiliations
Therapeutic Areas
Affiliations
University of Careggi, Italy
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
4 similar investigators found
Uwe Platzbecker, Prof.
Universitätsklinikum Leipzig
2 trials
Shared therapeutic areas:
Anemia in patients with very low, low or intermediate risk myelodysplastic neoplasms (MDS)Low Risk Myelodysplastic Syndromes
Worked with same sponsors:
European Myelodysplastic Neoplasms Cooperative GroupGCP-Service International West GmbH+6 more
Collaborated on 1 trial
Similarity Score24%
Krzysztof Mądry, Dr.
Medical University of Warsaw
1 trials
Shared therapeutic areas:
Anemia in patients with very low, low or intermediate risk myelodysplastic neoplasms (MDS)Low Risk Myelodysplastic Syndromes
Worked with same sponsors:
European Myelodysplastic Neoplasms Cooperative GroupGCP-Service International West GmbH+6 more
Collaborated on 1 trial
Similarity Score24%
Lionel Adès, Prof.
Service d'hématologie seniors Hôpital Saint-Louis, Paris
1 trials
Shared therapeutic areas:
Anemia in patients with very low, low or intermediate risk myelodysplastic neoplasms (MDS)Low Risk Myelodysplastic Syndromes
Worked with same sponsors:
European Myelodysplastic Neoplasms Cooperative GroupGCP-Service International West GmbH+6 more
Collaborated on 1 trial
Similarity Score24%
Diez Campelo, Dr.
University of Salamanca
1 trials
Shared therapeutic areas:
Anemia in patients with very low, low or intermediate risk myelodysplastic neoplasms (MDS)Low Risk Myelodysplastic Syndromes
Worked with same sponsors:
European Myelodysplastic Neoplasms Cooperative GroupGCP-Service International West GmbH+6 more
Collaborated on 1 trial
Similarity Score24%
Publications (0)
No publications found for this investigator.
Clinical Trials (1)
Showing 1 of 1 trials
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
Low Risk Myelodysplastic Syndromes
All 1 trials loaded